StreetInsider.com News Articles

iSpecimen ships hundreds of cancer specimens internationally in 3 weeks

Thu, 20 Aug 2026 16:06:37 -0400

iSpecimen Inc. (Nasdaq: ISPC) completed an international cancer research order involving hundreds of cancer blood specimens, with shipment occurring within three weeks of receiving the purchase order, according to a press release from the Woburn, Massachusetts-based company.

The project required large-scale biospecimen sourcing and fulfillment on an accelerated timeline. iSpecimen coordinated the sourcing and collection of specimens through its network of healthcare and research partners and managed international fulfillment to meet the project's deadline.

The company maintains a network of healthcare institutions, laboratories, biobanks, and research partners that supports the sourcing of specialized cancer specimens, including formalin-fixed, paraffin-embedded (FFPE) and flash-frozen tissue.

Chief

iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks

Thu, 20 Aug 2026 16:05:00 -0400

Woburn, MA, Aug. 20, 2026 (GLOBE NEWSWIRE) -- iSpecimen, a provider of human biospecimens, recently completed an international cancer research project involving hundreds of cancer blood specimens, with the samples shipped within three weeks of receiving the purchase order.

The project involved the coordination of large-scale biospecimen sourcing and fulfillment on an accelerated timeline. Through its network of healthcare and research partners, iSpecimen coordinated the sourcing and collection of the required specimens and managed international fulfillment to meet the project's timeline.

iSpecimen maintains a global and domestic network of healthcare institutions, laboratories, biobanks, and

iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks

Thu, 20 Aug 2026 16:05:00 -0400

iSpecimen maintains a global and domestic network of healthcare institutions, laboratories, biobanks, and

Form 8-K iSpecimen Inc. For: Aug 12

Fri, 14 Aug 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260814/26932730.html

Form 8-K iSpecimen Inc. For: Aug 12

Fri, 14 Aug 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260814/26932730.html

Form 10-Q iSpecimen Inc. For: Jun 30

Fri, 14 Aug 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260814/26932452.html

Form 10-Q iSpecimen Inc. For: Jun 30

Fri, 14 Aug 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260814/26932452.html

Form 8-K iSpecimen Inc. For: Aug 06

Tue, 11 Aug 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260811/26907128.html

Form 8-K iSpecimen Inc. For: Aug 06

Tue, 11 Aug 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260811/26907128.html

Form 8-K iSpecimen Inc. For: Aug 05

Fri, 07 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260807/26892006.html

Form 8-K iSpecimen Inc. For: Aug 05

Fri, 07 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260807/26892006.html

iSpecimen closes $5M public offering of stock and pre-funded warrants

Fri, 07 Aug 2026 16:30:08 -0400

iSpecimen Inc. (NASDAQ: ISPC), an online marketplace connecting researchers with biospecimen providers, announced the closing of a public offering that raised approximately $5.0 million.

The offering comprised 996,231 shares of common stock and pre-funded warrants to purchase up to 2,849,923 additional shares. E.F. Hutton & Co. served as the exclusive placement agent.

According to a press release, the company plans to use the proceeds to repay outstanding liabilities, pursue potential acquisitions of assets or investments in businesses, products and technologies, and fund marketing and advertising services. Remaining proceeds will be allocated to working capital.

The securities were offered under a registration statement on

iSpecimen closes $5 million public offering of stock and warrants

Fri, 07 Aug 2026 16:30:08 -0400

iSpecimen Inc. (NASDAQ: ISPC), an online marketplace connecting researchers with biospecimen providers, announced the closing of a public offering that raised approximately $5.0 million.

The offering consisted of 996,231 shares of common stock and pre-funded warrants to purchase up to 2,849,923 shares of common stock. E.F. Hutton & Co. served as the exclusive placement agent for the transaction.

The offering was made pursuant to a registration statement on Form S-1 initially filed with the Securities and Exchange Commission on June 24, 2026, and declared effective on July 30, 2026.

According to the company, proceeds will be directed toward repayment of outstanding liabilities, potential

iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants

Fri, 07 Aug 2026 16:30:00 -0400

WOBURN, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the closing of its previously announced public offering of an aggregate of 996,231 shares of the Company’s common stock and pre-funded warrants to purchase up to an aggregate of 2,849,923 shares of common stock, for an aggregate purchase price of approximately $5.0 million. The Company intends to use the proceeds of the offering for repayment of outstanding liabilities, potential

iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants

Fri, 07 Aug 2026 16:30:00 -0400

iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants

Fri, 07 Aug 2026 16:30:00 -0400

iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants

Fri, 07 Aug 2026 16:30:00 -0400

E.F. Hutton arranges $5M public offering for iSpecimen

Fri, 07 Aug 2026 15:46:08 -0400

E.F. Hutton & Co. served as the exclusive placement agent for a $5 million public offering for iSpecimen Inc. (Nasdaq: ISPC), according to a press release issued Aug. 7, 2026.

iSpecimen, which operates an online marketplace connecting medical researchers with biospecimen providers, said the capital raised will be used for repayment of outstanding liabilities, potential acquisitions and investments, marketing initiatives, and general corporate purposes.

The transaction is the third capital markets engagement between E.F. Hutton and iSpecimen since December 2025. E.F. Hutton has acted as exclusive placement agent on each of the financing transactions during that period.

Joseph T. Rallo, Chief Executive Officer

E.F. Hutton places $5M public offering for iSpecimen

Fri, 07 Aug 2026 15:45:28 -0400

E.F. Hutton & Co. served as exclusive placement agent for a $5 million public offering by iSpecimen Inc. (Nasdaq: ISPC), according to a press release from the investment bank.

iSpecimen, which operates an online marketplace connecting medical researchers with biospecimen providers, said it plans to use the proceeds to repay outstanding liabilities, fund potential acquisitions and investments, support marketing initiatives, and cover general corporate purposes.

The transaction is the third capital markets engagement between E.F. Hutton and iSpecimen since December 2025.

Joseph T. Rallo, Chief Executive Officer of E.F. Hutton, said: "We are pleased to once again support iSpecimen on another successful financing.

E.F. Hutton places $5M public offering for iSpecimen

Fri, 07 Aug 2026 15:45:28 -0400

E.F. Hutton & Co. served as exclusive placement agent for a $5 million public offering by iSpecimen Inc. (Nasdaq: ISPC), according to a press release from the investment bank.

The transaction is the third capital markets engagement between E.F. Hutton and iSpecimen since December 2025.

Joseph T. Rallo, Chief Executive Officer of E.F. Hutton, said: "We are pleased to once again support iSpecimen on another successful financing.

E.F. Hutton places $5M public offering for iSpecimen

Fri, 07 Aug 2026 15:45:28 -0400

E.F. Hutton & Co. served as exclusive placement agent for a $5 million public offering by iSpecimen Inc. (Nasdaq: ISPC), according to a press release from the investment bank.

The transaction is the third capital markets engagement between E.F. Hutton and iSpecimen since December 2025.

Joseph T. Rallo, Chief Executive Officer of E.F. Hutton, said: "We are pleased to once again support iSpecimen on another successful financing.

E.F. Hutton places $5M public offering for iSpecimen

Fri, 07 Aug 2026 15:45:28 -0400

E.F. Hutton & Co. served as exclusive placement agent for a $5 million public offering by iSpecimen Inc. (Nasdaq: ISPC), according to a press release from the investment bank.

The transaction is the third capital markets engagement between E.F. Hutton and iSpecimen since December 2025.

Joseph T. Rallo, Chief Executive Officer of E.F. Hutton, said: "We are pleased to once again support iSpecimen on another successful financing.

E.F. Hutton & Co. Acts as Acts as Exclusive Placement Agent for $5.0 Million Public Offering for iSpecimen

Fri, 07 Aug 2026 15:45:18 -0400

Transaction Marks E.F. Hutton's Third Capital Markets Engagement with iSpecimen Since December 2025

NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), a leading investment banking and financial advisory firm, today announced that it served as the exclusive placement agent in connection with the $5 million public offering for iSpecimen Inc. (Nasdaq: ISPC), an online global marketplace that connects researchers requiring biospecimens for medical research with a network of healthcare specimen providers.

The offering provides iSpecimen with additional capital to support its strategic priorities, including repayment of outstanding liabilities, potential

E.F. Hutton & Co. Acts as Acts as Exclusive Placement Agent for $5.0 Million Public Offering for iSpecimen

Fri, 07 Aug 2026 15:45:18 -0400

Transaction Marks E.F. Hutton's Third Capital Markets Engagement with iSpecimen Since December 2025

The offering provides iSpecimen with additional capital to support its strategic priorities, including repayment of outstanding liabilities, potential

E.F. Hutton & Co. Acts as Acts as Exclusive Placement Agent for $5.0 Million Public Offering for iSpecimen

Fri, 07 Aug 2026 15:45:00 -0400

The offering provides iSpecimen with additional capital to support its strategic priorities, including repayment of outstanding liabilities, potential acquisitions and investments, marketing initiatives, and general corporate purposes.

The